Emerging therapeutics for targeting Akt in cancer

Andrew Gdowski, Marlyn Panchoo, Timothy Van Treuren, Alakananda Basu

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt's importance in cell functions such as growth, proliferation and cell survival, many cancer cells rely on this pathway to aid in their survival. This dependence can lead to chemoresistance and selection of more adapted populations of cancer cells. Thus, it is important to understand the functional significance of isoform specificity and its relation to chemoresistance. In this review, we have summarized recent studies on Akt isoform specific regulation as well as each isoform's role in chemoresistance, emphasizing their potential as targets for cancer therapy. We have also condensed ongoing clinical studies involving various types of Akt inhibitors while highlighting the type of study, rationale and co-therapies involved in identifying Akt isoforms as promising therapeutic targets.

Original languageEnglish
Pages (from-to)757-768
Number of pages12
JournalFrontiers in Bioscience - Landmark
Volume21
Issue number4
StatePublished - 1 Jan 2016

Fingerprint

Protein Isoforms
Cells
Neoplasms
Therapeutics
Proto-Oncogene Proteins c-akt
Therapeutic Human Experimentation
Cell Survival
Growth
Proteins
Population

Keywords

  • Akt Inhibition
  • Akt Isoforms
  • Akt Regulation
  • Akt-mediated Chemoresistance
  • Clinical Trials
  • Review

Cite this

Gdowski, A., Panchoo, M., Van Treuren, T., & Basu, A. (2016). Emerging therapeutics for targeting Akt in cancer. Frontiers in Bioscience - Landmark, 21(4), 757-768.
Gdowski, Andrew ; Panchoo, Marlyn ; Van Treuren, Timothy ; Basu, Alakananda. / Emerging therapeutics for targeting Akt in cancer. In: Frontiers in Bioscience - Landmark. 2016 ; Vol. 21, No. 4. pp. 757-768.
@article{783ee952a3af4dd2a7660b98e6e9450d,
title = "Emerging therapeutics for targeting Akt in cancer",
abstract = "The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt's importance in cell functions such as growth, proliferation and cell survival, many cancer cells rely on this pathway to aid in their survival. This dependence can lead to chemoresistance and selection of more adapted populations of cancer cells. Thus, it is important to understand the functional significance of isoform specificity and its relation to chemoresistance. In this review, we have summarized recent studies on Akt isoform specific regulation as well as each isoform's role in chemoresistance, emphasizing their potential as targets for cancer therapy. We have also condensed ongoing clinical studies involving various types of Akt inhibitors while highlighting the type of study, rationale and co-therapies involved in identifying Akt isoforms as promising therapeutic targets.",
keywords = "Akt Inhibition, Akt Isoforms, Akt Regulation, Akt-mediated Chemoresistance, Clinical Trials, Review",
author = "Andrew Gdowski and Marlyn Panchoo and {Van Treuren}, Timothy and Alakananda Basu",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "21",
pages = "757--768",
journal = "Frontiers in Bioscience",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "4",

}

Gdowski, A, Panchoo, M, Van Treuren, T & Basu, A 2016, 'Emerging therapeutics for targeting Akt in cancer', Frontiers in Bioscience - Landmark, vol. 21, no. 4, pp. 757-768.

Emerging therapeutics for targeting Akt in cancer. / Gdowski, Andrew; Panchoo, Marlyn; Van Treuren, Timothy; Basu, Alakananda.

In: Frontiers in Bioscience - Landmark, Vol. 21, No. 4, 01.01.2016, p. 757-768.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Emerging therapeutics for targeting Akt in cancer

AU - Gdowski, Andrew

AU - Panchoo, Marlyn

AU - Van Treuren, Timothy

AU - Basu, Alakananda

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt's importance in cell functions such as growth, proliferation and cell survival, many cancer cells rely on this pathway to aid in their survival. This dependence can lead to chemoresistance and selection of more adapted populations of cancer cells. Thus, it is important to understand the functional significance of isoform specificity and its relation to chemoresistance. In this review, we have summarized recent studies on Akt isoform specific regulation as well as each isoform's role in chemoresistance, emphasizing their potential as targets for cancer therapy. We have also condensed ongoing clinical studies involving various types of Akt inhibitors while highlighting the type of study, rationale and co-therapies involved in identifying Akt isoforms as promising therapeutic targets.

AB - The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt's importance in cell functions such as growth, proliferation and cell survival, many cancer cells rely on this pathway to aid in their survival. This dependence can lead to chemoresistance and selection of more adapted populations of cancer cells. Thus, it is important to understand the functional significance of isoform specificity and its relation to chemoresistance. In this review, we have summarized recent studies on Akt isoform specific regulation as well as each isoform's role in chemoresistance, emphasizing their potential as targets for cancer therapy. We have also condensed ongoing clinical studies involving various types of Akt inhibitors while highlighting the type of study, rationale and co-therapies involved in identifying Akt isoforms as promising therapeutic targets.

KW - Akt Inhibition

KW - Akt Isoforms

KW - Akt Regulation

KW - Akt-mediated Chemoresistance

KW - Clinical Trials

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85016098532&partnerID=8YFLogxK

M3 - Review article

VL - 21

SP - 757

EP - 768

JO - Frontiers in Bioscience

JF - Frontiers in Bioscience

SN - 1093-9946

IS - 4

ER -

Gdowski A, Panchoo M, Van Treuren T, Basu A. Emerging therapeutics for targeting Akt in cancer. Frontiers in Bioscience - Landmark. 2016 Jan 1;21(4):757-768.